pentobarbital will decrease the level or outcome of diazepam intranasal by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch. Strong or reasonable CYP3A4 inducers may well raise level of diazepam elimination; consequently, efficacy of diazepam may very well be decreased.

pentobarbital will minimize the level or influence of armodafinil by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unidentified.

pentobarbital will reduce the extent or outcome of alfuzosin by impacting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Unidentified.

pentobarbital will decrease the level or impact of pantoprazole by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Minor/Significance Unidentified.

pentobarbital will lower the extent or effect of vinblastine by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Significance Not known.

pentobarbital will lessen the extent or impact of irinotecan liposomal by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Use Caution/Watch.

pentobarbital and daridorexant both equally increase sedation. Modify Therapy/Keep track of Carefully. Coadministration boosts chance of CNS despair, which may lead to additive impairment of psychomotor effectiveness and cause daytime impairment.

pentobarbital will lessen the extent or influence of dutasteride by influencing hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Importance Unknown.

pentobarbital will reduce the level or influence of piroxicam by influencing hepatic enzyme read more CYP2C9/10 metabolism. Small/Significance Mysterious.

This drug may perhaps interfere with the absorption of orally administered griseofulvin, lowering its blood concentrations; effects of blood level reduction mysterious; preferable to prevent concomitant administration of these drugs

pentobarbital will decrease the level or influence of alfentanil by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Slight/Importance Unknown.

Monitor Carefully (1)pentobarbital will reduce the level or effect of glecaprevir/pibrentasvir by influencing hepatic/intestinal enzyme CYP3A4 metabolism.

Training warning when administered to clients with acute or Serious agony; could result in paradoxical excitement or essential signs may be masked

pentobarbital will minimize the level or influence of zaleplon by affecting hepatic/intestinal enzyme CYP3A4 metabolism. Insignificant/Significance Not known.